This study aims to assess analgesia efficacy between liposomal bupivacaine single injection interscalene blockade vs. continuous interscalene nerve block for patients undergoing primary total shoulder arthroplasty.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
88
Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Pain Intensity Score at Rest at 24 Hours Post-operatively
Self-reported pain intensity scores measure using numerical rating scale of 0 (no pain) to 10 (worst pain imaginable). Primary outcome was measured at 24 hours postoperative time point.
Time frame: Post-Operative Day 1
Cumulative Opioid Consumption
Reported in mg oral morphine equivalents (OME); measured from PACU through postoperative day 3
Time frame: PACU to postoperative day 3
Quality of Recovery Score (QoR)
15 item short form patient survey using a scoring system evaluating 5 dimensions of health: psychological support, comfort, emotions, physical independence, and pain. The 11-point numerical rating scale leads to a minimum score of 0 (very poor recovery) and a maximum score of 150 (excellent recovery).
Time frame: Post-Operative Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.